Adherence to Adjuvant Hormonal Therapy and Associated Factors Among Women with Breast Cancer Attending the Tikur Anbessa Specialized Hospital, Addis Ababa Ethiopia, 2019: A Cross-sectional Study.
Ethiopia
adherence
adjuvant hormone therapy
breast cancer
Journal
Breast cancer (Dove Medical Press)
ISSN: 1179-1314
Titre abrégé: Breast Cancer (Dove Med Press)
Pays: New Zealand
ID NLM: 101591856
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
03
2021
accepted:
21
05
2021
entrez:
17
6
2021
pubmed:
18
6
2021
medline:
18
6
2021
Statut:
epublish
Résumé
In breast cancer patients, adherence to adjuvant hormone therapy (AHT) is uncertain. Seven in every 10 patients were hormone receptor positive and adjuvant hormone therapy (AHT) is prescribed for 5-10 years for a woman with breast cancer. Therefore, the aim of this research was to examine adherence to adjuvant hormone therapy and related factors among women with breast cancer attending the Tikur Anbessa Specialized Hospital Oncology Center. An institutional-based cross-sectional study was conducted from March to April, 2019. Systematic random sampling technique was used to select participants. A semi-structured questionnaire was used. Medication possession ratio (MPR) was used where score ≥80% was adherence. Data were entered in EpiData version 4.4.2.1 and transferred to SPSS version 25, and analyzed using binary logistic regression. Out of 216 women with breast cancer 209 participated in the study with a response rate of 97%. The overall adherence in this study was 77.5%. Getting social support (OR=3.959, 95%CI: 1.570-9.980), being on anastrozole (OR=0.139, 95%CI: 0.040-0.485), getting a thorough therapeutic communication about treatment (OR=4.590, 95%CI: 1.061-19.863), undergoing mastectomy (OR=0.215, 95%CI: 0.059-0.788), having side effects (OR=0.210, 95%CI: 0.085-0.517) were found to be significantly associated with adherence to AHT. In general, the overall adherence to AHT was 77.5% for women with breast cancer. Factors such as types of adjuvant hormone therapy, lack of side effects, mastectomy, getting social support, and thorough therapeutic communication were strongly linked with adherence to them.
Sections du résumé
BACKGROUND
BACKGROUND
In breast cancer patients, adherence to adjuvant hormone therapy (AHT) is uncertain. Seven in every 10 patients were hormone receptor positive and adjuvant hormone therapy (AHT) is prescribed for 5-10 years for a woman with breast cancer. Therefore, the aim of this research was to examine adherence to adjuvant hormone therapy and related factors among women with breast cancer attending the Tikur Anbessa Specialized Hospital Oncology Center.
METHODS
METHODS
An institutional-based cross-sectional study was conducted from March to April, 2019. Systematic random sampling technique was used to select participants. A semi-structured questionnaire was used. Medication possession ratio (MPR) was used where score ≥80% was adherence. Data were entered in EpiData version 4.4.2.1 and transferred to SPSS version 25, and analyzed using binary logistic regression.
RESULTS
RESULTS
Out of 216 women with breast cancer 209 participated in the study with a response rate of 97%. The overall adherence in this study was 77.5%. Getting social support (OR=3.959, 95%CI: 1.570-9.980), being on anastrozole (OR=0.139, 95%CI: 0.040-0.485), getting a thorough therapeutic communication about treatment (OR=4.590, 95%CI: 1.061-19.863), undergoing mastectomy (OR=0.215, 95%CI: 0.059-0.788), having side effects (OR=0.210, 95%CI: 0.085-0.517) were found to be significantly associated with adherence to AHT.
CONCLUSION
CONCLUSIONS
In general, the overall adherence to AHT was 77.5% for women with breast cancer. Factors such as types of adjuvant hormone therapy, lack of side effects, mastectomy, getting social support, and thorough therapeutic communication were strongly linked with adherence to them.
Identifiants
pubmed: 34135629
doi: 10.2147/BCTT.S311445
pii: 311445
pmc: PMC8200251
doi:
Types de publication
Journal Article
Langues
eng
Pagination
383-392Informations de copyright
© 2021 Wako et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Oncology. 2006;71(1-2):1-9
pubmed: 17344666
Support Care Cancer. 2020 Jan;28(1):271-278
pubmed: 31037379
Breast Dis. 2010;31(1):33-41
pubmed: 21109721
Expert Rev Anticancer Ther. 2018 Nov;18(11):1101-1112
pubmed: 30188738
Asia Pac J Oncol Nurs. 2017 Oct-Dec;4(4):283-289
pubmed: 28966955
Breast Cancer Res Treat. 2018 Jul;170(1):111-118
pubmed: 29479644
Biomed Res Int. 2015;2015:217047
pubmed: 26539470
Breast Cancer Res Treat. 2012 Jul;134(2):459-78
pubmed: 22689091
N Engl J Med. 2005 Aug 4;353(5):487-97
pubmed: 16079372
Breast Cancer Res Treat. 2015 Jul;152(2):419-27
pubmed: 26070268
Clin J Oncol Nurs. 2014 Jun;18(3):E50-7
pubmed: 24867124
Breast. 2011 Apr;20 Suppl 2:S51-3
pubmed: 21295480
J Manag Care Spec Pharm. 2016 Aug;22(8):969-78
pubmed: 27459660
Breast Cancer Res Treat. 2018 Nov;172(1):167-177
pubmed: 30030708
Bull Cancer. 2013 Oct;100(10):1007-15
pubmed: 24113516
Prof Inferm. 2016 Apr-Jun;69(4):113-21
pubmed: 27600553
Clin Oncol (R Coll Radiol). 2018 Jan;30(1):e9-e15
pubmed: 29103853
Patient Prefer Adherence. 2018 Feb 16;12:291-300
pubmed: 29497284
Patient Prefer Adherence. 2018 May 22;12:887-897
pubmed: 29872274
Patient Prefer Adherence. 2016 Sep 30;10:2007-2019
pubmed: 27757021
BMC Cancer. 2014 Jun 03;14:397
pubmed: 24893670
Arch Pathol Lab Med. 2011 Feb;135(2):194-9
pubmed: 21284437
Breast Cancer Res Treat. 2018 Feb;167(3):615-633
pubmed: 29110151
Anticancer Res. 2020 Feb;40(2):857-864
pubmed: 32014929
Nurs Res. 2013 Jul-Aug;62(4):243-51
pubmed: 23817282
Breast Cancer Res Treat. 2011 Apr;126(2):529-37
pubmed: 20803066
Clin J Oncol Nurs. 2008 Apr;12(2):213-21
pubmed: 18390458
Acta Oncol. 2018 Jul;57(7):935-940
pubmed: 29493327
Cancer. 2017 May 15;123(6):940-947
pubmed: 27780311
Lancet. 2005 May 14-20;365(9472):1687-717
pubmed: 15894097
Am J Clin Oncol. 2020 Jul;43(7):504-509
pubmed: 32251120
Cancer Epidemiol. 2018 Apr;53:93-98
pubmed: 29414637
Breast Cancer Res Treat. 2013 Feb;137(3):829-36
pubmed: 23263740
Lancet Oncol. 2013 Apr;14(4):e158-67
pubmed: 23561747
Patient Prefer Adherence. 2017 Feb 23;11:305-322
pubmed: 28260867
Lancet. 2016 Feb 27;387(10021):857-65
pubmed: 26686960
Breast Cancer Res Treat. 2018 Aug;170(3):623-631
pubmed: 29671113
Breast. 2018 Dec;42:23-30
pubmed: 30149234
Ir J Med Sci. 2016 May;185(2):383-92
pubmed: 25971465